IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A liquid formulation comprising

- a) human growth hormone (hGH);
- b) polyethylene-polypropylene glycol;
- c) a citrate buffer;
- d) 60 to 100 mg/ml of sucrose, and
- e) phenol.

Claims 2-5 (Cancelled).

Claim 6 (Previously Presented): The formulation according to claim 1, comprising citrate in a concentration ranging from 1 to 100 mM.

Claim 7 (Previously Presented): The formulation according to claim 1, having a pH in the range of 5 to 7.

Claim 8 (Previously Presented): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration ranging from 0.5 to 5 mg/ml.

Claim 9 (Previously Presented): The formulation according to claim 1, wherein the polyethylene-polypropylene glycol is a block copolymer of ethylene oxide and propylene oxide.

2

Application No. 10/549,763

Reply to Office Action of December 31, 2009

Claim 10 (Previously Presented): The formulation according to claim 9, wherein the

propylene oxide block is sandwiched between two ethylene oxide blocks.

Claim 11 (Cancelled)

Claim 12 (Currently Amended): [[A]] The formulation according to claim 1, wherein

the phenol is present in a concentration ranging from 1 to 10 mg/ml.

Claims 13-14 (Cancelled).

Claim 15 (Previously Presented): The formulation according to claim 1, the

formulation having a pH of 5.9 and consisting of r-hGH, sucrose, Poloxamer 188, citric acid,

phenol and optionally water for injection.

Claims 16-17 (Cancelled).

Claim 18 (Previously Presented): A pharmaceutical composition comprising the

formulation according to claim 1.

Claim 19 (Previously Presented): The liquid formulation according to claim 1,

wherein the formulation is hermetically closed in a sterile condition within a container suited

for storage before use.

Claim 20 (Cancelled):

3

Claim 21 (Currently Amended): The formulation according to claim 1 [[4]], comprising sucrose in a concentration at about 60 mg/ml.

Claim 22 (Previously Presented): The formulation according to claim 1, comprising citrate in a concentration ranging from 5 to 50 mM.

Claim 23 (Previously Presented): The formulation according to claim 1, comprising citrate in a concentration ranging from 10 to 20 mM.

Claim 24 (Previously Presented): The formulation according to claim 1, having a pH in the range of 5.5 to 6.5.

Claim 25 (Previously Presented): The formulation according to claim 1, having a pH at about 6.

Claim 26 (Previously Presented): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration ranging from 1 to 2 mg/ml.

Claim 27 (Previously Presented): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration at 1.5 mg/ml.

Claim 28 (Currently Amended): [[A]] <u>The</u> formulation according to claim <u>1</u> [[11]], comprising the preservative <u>phenol</u> in a concentration ranging from 2 to 5 mg/ml.

Application No. 10/549,763 Reply to Office Action of December 31, 2009

Claim 29 (Currently Amended): [[A]] <u>The</u> formulation according to claim <u>1</u> [[11]], comprising the preservative <u>phenol</u> in a concentration at 3 mg/ml.